BRPI0514265A - método para detectar cáncer da tireóide em um paciente, e, ensaio pré-operatório para determinar se a neoplasia da tireóide em um paciente é benigna ou maligna - Google Patents

método para detectar cáncer da tireóide em um paciente, e, ensaio pré-operatório para determinar se a neoplasia da tireóide em um paciente é benigna ou maligna

Info

Publication number
BRPI0514265A
BRPI0514265A BRPI0514265-2A BRPI0514265A BRPI0514265A BR PI0514265 A BRPI0514265 A BR PI0514265A BR PI0514265 A BRPI0514265 A BR PI0514265A BR PI0514265 A BRPI0514265 A BR PI0514265A
Authority
BR
Brazil
Prior art keywords
patient
thyroid cancer
preoperative
assay
detecting
Prior art date
Application number
BRPI0514265-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Manjula Gupta
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of BRPI0514265A publication Critical patent/BRPI0514265A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0514265-2A 2004-08-11 2005-08-11 método para detectar cáncer da tireóide em um paciente, e, ensaio pré-operatório para determinar se a neoplasia da tireóide em um paciente é benigna ou maligna BRPI0514265A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60058904P 2004-08-11 2004-08-11
PCT/US2005/028688 WO2006020837A2 (en) 2004-08-11 2005-08-11 Method of detecting thyroid cancer

Publications (1)

Publication Number Publication Date
BRPI0514265A true BRPI0514265A (pt) 2008-06-10

Family

ID=35908168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514265-2A BRPI0514265A (pt) 2004-08-11 2005-08-11 método para detectar cáncer da tireóide em um paciente, e, ensaio pré-operatório para determinar se a neoplasia da tireóide em um paciente é benigna ou maligna

Country Status (8)

Country Link
US (1) US20070065833A1 (https=)
EP (1) EP1778872A2 (https=)
JP (1) JP2008509672A (https=)
KR (1) KR20070044048A (https=)
AU (2) AU2005272696A1 (https=)
BR (1) BRPI0514265A (https=)
CA (1) CA2576912A1 (https=)
WO (1) WO2006020837A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US8394580B2 (en) * 2007-08-17 2013-03-12 The Johns Hopkins University Protein markers for the detection of thyroid cancer metastasis
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
WO2010056374A2 (en) 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20110312520A1 (en) 2010-05-11 2011-12-22 Veracyte, Inc. Methods and compositions for diagnosing conditions
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
WO2014151764A2 (en) 2013-03-15 2014-09-25 Veracyte, Inc. Methods and compositions for classification of samples
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN109219445B (zh) * 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (en) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
CN108089011A (zh) * 2018-01-09 2018-05-29 广州市康润生物科技有限公司 一种快速免疫检测系统在手术中的新用途
KR102526916B1 (ko) * 2019-04-05 2023-05-02 주식회사 제놉시 Cfdna를 이용한 위암 진단방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391579B1 (en) * 1996-02-01 2002-05-21 Albert Einstein College Of Medicine Of Yeshiva University Thyroid sodium/iodide symporter and nucleic acid encoding same
US6066449A (en) * 1997-04-15 2000-05-23 The Trustees Of Columbia University In The City Of New York Method of detecting metastatic thyroid cancer
AU7830598A (en) * 1997-06-10 1998-12-30 Michael A. Levine Methods for thyroid cell detection
US20020009778A1 (en) * 1998-05-29 2002-01-24 Incyte Pharmaceuticals, Inc. Thyroid and pituitary membrane protein
US6436642B1 (en) * 1999-04-20 2002-08-20 Curagen Corporation Method of classifying a thyroid carcinoma using differential gene expression

Also Published As

Publication number Publication date
AU2005272696A1 (en) 2006-02-23
EP1778872A2 (en) 2007-05-02
JP2008509672A (ja) 2008-04-03
WO2006020837A3 (en) 2006-09-28
AU2009210417A1 (en) 2009-09-10
CA2576912A1 (en) 2006-02-23
KR20070044048A (ko) 2007-04-26
US20070065833A1 (en) 2007-03-22
WO2006020837A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
BRPI0514265A (pt) método para detectar cáncer da tireóide em um paciente, e, ensaio pré-operatório para determinar se a neoplasia da tireóide em um paciente é benigna ou maligna
Lamb et al. Epi proColon® 2.0 CE: a blood-based screening test for colorectal cancer
AU2013325120B2 (en) Diagnostic devices and methods
Hiramatsu et al. N 1, N 12-diacetylspermine as a sensitive and specific novel marker for early-and late-stage colorectal and breast cancers
RU2716494C2 (ru) Способ детекции нуклеосом, содержащих гистоновые варианты
Bartsch et al. Nocturnal urinary 6‐sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age‐matched controls and shows negative correlation with tumor‐size
BRPI0513692B8 (pt) processos para detecção de câncer de bexiga em um indivíduo
Bhagirath et al. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
EP1842065A4 (en) METHODS OF DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS
EP1838867A4 (en) APOLIPOPROTEIN A II ISOFORM AS A BIOMARKER FOR PROSTATE CANCER
EP1183390B8 (en) METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY hCG ASSAY
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
Sulaieva et al. Thyroid stimulating hormone levels and BRAFV600E mutation contribute to pathophysiology of papillary thyroid carcinoma: relation to outcomes?
Fujimoto et al. Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers
Banfalvi et al. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma
Moradi et al. Quantitative detection of SRY-Box 21 (SOX21) gene promoter methylation as a stool-based noninvasive biomarker for early diagnosis of colorectal cancer by MethyLight method
US20160312300A1 (en) Assays and methods relating to the treatment of melanoma
Baron et al. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women
BRPI0315735A8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
BR0116010A (pt) Kit imunoterapêutico para o tratamento de tumores
Li et al. Expression of survivin and caspase 3 in oral squamous cell carcinoma and peritumoral tissue
Poon et al. Correlation and prognostic significance of beta-galactoside alpha-2, 6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma
CA2422538A1 (en) Notch receptor agonists and uses
Tsao et al. Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.